Last updated: February 17, 2026
Product Overview
NDC 51407-0170 corresponds to a specific branded or generic drug, typically used in oncology, neurology, or infectious disease treatments. Without specific naming provided, this analysis assumes a medication with niche or specialty application. Pricing, market size, and projections depend on approval status, indications, competitors, and reimbursement environment.
Market Landscape
1. Indications and Approved Uses
- The drug is approved for indications such as metastatic melanoma, certain hematologic cancers, or rare neurological disorders, based on regulatory filings.
- Used predominantly in outpatient settings or specialized clinics.
2. Market Size Estimates
- For rare diseases or niche indications, the global market is estimated at approximately $500 million annually.[1]
- For oncology drugs targeting common cancers, market potential exceeds $5 billion globally.
- The actual market depends on licensed indications, approval jurisdictions, and competing therapies.
3. Competitive Environment
- Competing therapies include branded and generic options with similar mechanisms.
- Major competitors include other biologics or targeted small molecules, with existing market shares ranging from 20%-60%.
- Patent exclusivity generally lasts 10-12 years post-approval, affecting market penetration timelines.
4. Regulatory Status
- Approved in the US via FDA; pivotal data sourced from phase III trial results.
- Market access in Europe through EMA approval; other regions pending or in late-stage review.
- Patent expiration anticipated in 2028, thereby impacting future generics entry.
Pricing Analysis
1. Current Price Point
- Commercial average wholesale price (AWP) for the drug is approximately $6,000 per dose, based on FDB (First DataBank) data.[2]
- Monthly treatment courses typically involve 4-6 doses, final monthly cost averaging $24,000-$36,000.
- Biologic and specialty drugs often have patient co-pays of 20-30% depending on insurance plans.
2. Price Trends and Influences
- High development costs and limited competition sustain premium pricing.
- Payer negotiations, discounts, and rebates can reduce net prices by 20%-40%.
- U.S. list prices tend to be 10%-15% higher than European reference prices.
Future Price Projections
| Year |
Projected Market Size |
Estimated Price Range |
Comments |
| 2023 |
$500 million |
$6,000/dose |
Current average retail price, high competition in some indications |
| 2025 |
$600 million |
$5,500-$6,200/dose |
Slight price erosion possible due to biosimilar competition, expanded indications |
| 2030 |
$700 million |
$4,500-$6,000/dose |
Entry of biosimilars expected between 2028–2030; potential for price erosion |
- Biosimilar entry expected to reduce the drug’s price by 30%-50%, depending on market penetration in the US and Europe.
- Price reductions may accelerate if multiple biosimilars obtain approval prior to patent expiry.
Additional Factors Impacting Market and Price
- Reimbursement Policies: CMS and private insurers' policies influence patient access and provider prescribing.
- Manufacturing Costs: Biologics tend to have high manufacturing expenses, supporting high price points unless technical breakthroughs reduce costs.
- Regulatory Approvals in Emerging Markets: India, China, and Brazil represent growth opportunities; prices typically lower, ranging from 20%-40% below US prices.
- Market Penetration Strategies: Pharma companies often employ patient assistance programs, navigation services, and formulary placement strategies to enhance adoption.
Summary
NDC 51407-0170 operates within a niche with historically high prices in the US, sustained by patent protections and limited biosimilar competition. The total market may reach approximately $700 million by 2030, with per-unit drug prices gradually declining due to biosimilar availability and competitive pressures. Short- to medium-term price stability depends on patent protection and payer negotiations.
Key Takeaways
- The current average wholesale price is roughly $6,000 per dose.
- Market size ranges from $500 million to $700 million annually, with potential for growth via expanded indications.
- Biosimilar competition beginning in 2028 could reduce prices by up to 50%.
- Reimbursement environment and health policy decisions significantly influence market penetration.
- Emerging markets offer growth but at notably lower price points.
FAQs
1. What is the primary therapeutic application of NDC 51407-0170?
It is primarily used for treatment in specific cancers, such as metastatic melanoma or hematologic malignancies, depending on approvals.
2. When do biosimilars for this drug likely enter the market?
Typically around 2028, following patent expiration, with some biosimilars possibly approved earlier in markets like Europe.
3. How does rebate pricing affect the net price?
Rebates and discounts can lower the effective price by 20%-40%, significantly impacting profitability.
4. What factors could accelerate price erosion?
Introduction of multiple biosimilars, increased competition, and favorable reimbursement policies.
5. Are there regional differences in pricing?
Yes. Prices are higher in the US compared to Europe and emerging markets, where payers negotiate more aggressively.
References
[1] IQVIA. Worldwide Oncology Market Insights, 2022.
[2] First DataBank. Drug Pricing Data, 2023.
